1. Goal Attainment: A Clinically Meaningful Measure of Success of Botulinum Toxin-A Treatment for Lower Limb Spasticity in Ambulatory Patients
- Author
-
Subbuh Choudhry, MBBS, Benjamin L. Patritti, PhD, Richard Woodman, PhD, Paul Hakendorf, MPH, and Lydia Huang, MBBS
- Subjects
Botulinum toxins ,Botulinum toxins, type A ,Gait ,Goals ,Lower extremity ,Muscle spasticity ,Medicine (General) ,R5-920 - Abstract
Objectives: The objectives of this study were to evaluate whether botulinum toxin type A (BoNT-A) treatment for lower limb spasticity leads to patient goal attainment and identify factors associated with positive goal attainment and to assess the effect of BoNT-A treatment on patients’ gait. Design: Retrospective cohort study between June 2014 and February 2019. Setting: Public outpatient spasticity clinic in a tertiary hospital. Participants: Thirty patients (N=30; 50% female; average age, 50.5y) with lower limb spasticity of heterogenous etiologies (96.7% cerebral±spinal origin and 3.3% isolated spinal origin); 73.3% (N=22) of patients had previously received BoNT-A treatment. Interventions: BoNT-A injection to lower limb muscles. Main Outcome Measures: The primary outcome measure was goal attainment measured using Goal Attainment Scaling. The Modified Ashworth Scale (MAS) was used to assess spasticity. Gait was characterized by spatiotemporal parameters. Results: Fifty-six treatment episodes were analyzed and showed that BoNT-A treatment resulted in a significant reduction in spasticity (pretreatment MAS=3.18±0.73; posttreatment MAS=2.27±0.89; P more...
- Published
- 2021
- Full Text
- View/download PDF